After months of struggle, the U.N.-backed Covax alliance will soon have many more doses, promising relief for vaccine shortages in poorer countries. But it faces a deepening crisis: difficulties getting shots into arms as the Delta variant spreads.
By Benjamin Mueller and Rebecca Robbins
Aug. 2, 2021
Deaths from Covid-19 were surging across Africa in June when 100,000 doses of the Pfizer-BioNTech vaccine arrived in Chad. The delivery seemed proof that the United Nations-backed program to immunize the world could get the most desirable vaccines to the least developed nations. Yet five weeks later, Chad’s health minister said, 94,000 doses remained unused.